Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Royal Philips (Koninklijke Philips N.V., NYSE: PHG) is a health technology company whose news flow centers on diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health. Company announcements frequently highlight AI-enabled systems, new product launches and strategic portfolio moves, giving investors and observers insight into how Philips develops and positions its health technology offerings.
Recent Philips news has featured AI-powered innovations in image-guided therapy and diagnostic imaging, such as LumiGuide 3D Device Guidance for light-based navigation during minimally invasive procedures, DeviceGuide for AI-assisted tracking of heart valve repair devices, and Verida, a detector-based spectral CT system with AI integrated across the imaging chain. The company also reports advances in MRI through its BlueSeal Horizon 3.0T platform and extended partnerships in neuroimaging, such as the integration of Cortechs.ai quantitative analytics into Philips MR workflows.
News items also cover enterprise informatics and cloud-based solutions, including the launch of Philips Management 15, a web-based diagnostic viewer that delivers full radiology capabilities through a browser and interfaces with AI tools and interactive reporting. In addition, Philips communicates on long-term partnerships with health systems, monitoring agreements and large-scale deployments of its Azurion image-guided therapy systems.
Corporate and portfolio developments appear regularly in the news stream. Examples include the agreement to acquire SpectraWAVE Inc. to expand intravascular imaging and physiology solutions, and the completed carve-out of the Philips Emergency Care business, which now operates as Heartstream under a Philips brand license. Earnings-related releases and Form 6-K summaries provide context on comparable order intake, sales trends, margins, productivity programs and outlook.
Investors and healthcare professionals following PHG news can use this page to track product introductions, AI and imaging milestones, strategic transactions and quarterly performance updates that shape Philips’ role in global health technology.
Summary not available.
Royal Philips (NYSE: PHG) has formed a strategic partnership with TriHealth to enhance cardiac care through Philips’ innovative cardiology solutions. This collaboration will support the new TriHealth Heart & Vascular Institute at Bethesda North Hospital, facilitating exceptional patient care and medical education. The facility will feature nine interventional suites equipped with advanced Philips imaging technologies that promote efficient workflows and improved outcomes. The agreement emphasizes TriHealth's commitment to quality care and its integration with Philips' technology management plans, ensuring access to the latest innovations in heart health.
Royal Philips (NYSE: PHG) announced a strategy focused on organic growth and scalable innovation to enhance performance and create sustainable value. Despite operating in healthy market segments with annual growth of 3-6% and mid-to-high-teens margins, Philips faces significant operational challenges reflected in its 2022 performance. The company aims for mid-single-digit comparable sales growth and a low-teens Adjusted EBITA margin by 2025. Key initiatives include improving patient safety, enhancing supply chain reliability, and simplifying its operating model. Additionally, Philips plans to reduce its workforce by a total of 10,000 roles by 2025 to align with its strategic goals.
Philips reported Q4 2022 sales of EUR 5.4 billion, a 3% comparable sales growth driven by improved component supplies, despite ongoing supply chain challenges. Order intake decreased by 8%, primarily due to reduced demand for COVID-19-related products. Full-year sales fell to EUR 17.8 billion, a 3% decline, largely attributed to operational hurdles and geopolitical factors. Adjusted EBITA for Q4 was EUR 651 million (12% margin). The company anticipates low-single-digit sales growth and improved EBITA in 2023, while maintaining a dividend of EUR 0.85 per share. CEO Roy Jakobs emphasized efforts to enhance patient safety and quality management amidst challenging conditions.
The Michigan Department of Health and Human Services (MDHHS) has partnered with Royal Philips (NYSE: PHG) to enhance maternal and infant health in Michigan. The Philips Pregnancy+ mobile app, with over 55 million downloads, will be made accessible to Medicaid-eligible families, accounting for 45% of births in the state. This initiative aims to improve health outcomes by directing users to various state programs, such as home visiting services and breastfeeding resources. MDHHS expects this partnership to address access barriers in maternal care, particularly for underrepresented communities.
Royal Philips (NYSE: PHG) has received a perfect score of 5 out of 5 from Forbes Magazine for its Pregnancy+ Application, recognized in the list of the “Best Pregnancy Apps of 2023.” The app, with over 55 million downloads, provides personalized content and expert information to support parents from pregnancy onset through various stages. Forbes praised the app for its comprehensive features, including daily tailored articles and guides on breastfeeding and exercise. Philips remains a global leader in health technology, focusing on improving health outcomes with integrated solutions.
Masimo (NASDAQ: MASI) and Royal Philips (NYSE: PHG) have announced an expansion of their partnership to enhance patient monitoring for home telehealth applications with the Masimo W1™ watch. This innovative technology will integrate Masimo's advanced health tracking with Philips's patient monitoring ecosystem, offering continuous, remote monitoring of vital health data. The combined solution aims to support early discharge initiatives and chronic illness management. The Masimo W1 is CE marked and awaiting FDA clearance. This development will be showcased at Arab Health 2023, highlighting advancements in telehealth.
Royal Philips (NYSE: PHG) announced an update regarding its subsidiary Philips Respironics' program addressing health risks linked to the foam in CPAP, BiPAP, and mechanical ventilator devices. The company confirmed that testing for first-generation DreamStation devices is complete, revealing that approximately 68% of these devices were not exposed to ozone cleaning as per usage instructions. Independent laboratories and external medical experts conducted the assessments, providing a comprehensive review.
Royal Philips (NYSE: PHG) has partnered with MagCorp to explore high-temperature superconducting MRI magnets that don't require helium cooling. This collaboration aims to enhance MRI accessibility and sustainability, potentially lowering costs while reducing environmental impact. The new technology could decrease the size and weight of MRI machines and expand patient access, especially in underserved areas. Philips has already introduced BlueSeal magnet technology, leading the market in helium-free MRI solutions. The partnership focuses on developing superconductors that operate at higher temperatures and are based on more abundant materials.
On November 28, 2022, Philips unveiled its next-generation Advanced Visualization Workspace at the RSNA annual meeting in Chicago. This platform features new cardiac MR Suite workflows, AI-powered CT ASPECT Scoring, and enhanced CT Liver Analysis applications. It aims to integrate diagnostics across multiple specialties, improving clinical efficiency and diagnostic accuracy. With over 70 applications, the workspace supports real-time analysis and communication, enhancing patient care. Philips also introduced a new Radiology Information System that streamlines departmental workflows and patient scheduling.